News and Information

VIDA Diagnostics Appoints Philippe Raffy, Ph.D. Chief Technology Officer

FOR IMMEDIATE RELASE - Coralville, IA – March 28, 2012 - VIDA Diagnostics, a leading developer of quantitative pulmonary imaging software, announced today that the company has appointed Philippe Raffy, Ph.D. as Chief Technology Officer (CTO). Dr. Raffy's inclusion to the VIDA management team strengthens the technical leadership and expertise in pulmonary image analysis.

"Dr. Raffy's unique background and experience in pulmonary imaging and machine vision solidify VIDA's position as leading experts in quantitative imaging of the lung," said Susan A. Wood, Ph.D., President and CEO of VIDA. "Philippe's experience in commercializing medical imaging technologies into developing markets is an essential inclusion to our team as VIDA continues its growth trajectory."

"I welcome the opportunity to expand VIDA's quantitative imaging solutions for the early detection, diagnosis and treatment of pulmonary disease into clinical practice," said Dr. Raffy. "Chronic Obstructive Pulmonary Diseases (COPD) and lung cancer cause increasingly prominent public health disorders, creating major economic challenges for our societies and healthcare systems. They require disruptive approaches to targeted diagnoses and treatment planning."

Prior to VIDA, Dr. Raffy held technical and management leadership positions at R2 Technologies, Inc. and Vital Images, Inc., where he was instrumental in commercializing innovative medical imaging technologies. Dr. Raffy has a Masters and Ph.D. in Electrical Engineering from University of Nice-Sophia Antipolis and a postdoctoral fellowship at Stanford University's Information Systems Laboratory. He is an inventor of seven US and EEU patents and 37 peer reviewed publications.

Download Release >>

About VIDA Diagnostics
VIDA Diagnostics is a leader in clinically-validated quantitative pulmonary analysis software for the early detection, evaluation and aiding of treatment of pulmonary disease including COPD, emphysema, lung cancer, and asthma. FDA approved and CE certified, VIDA's analysis methodology has been successfully tested in multiple academic, pulmonary device, and pharmaceutical clinical trials. For more information on VIDA Diagnostics, visit www.vidadiagnostics.com

About Emphysema/COPD
The global incidence of Chronic Obstructive Pulmonary Disease (COPD), which includes emphysema, is on the rise and will become the third leading cause of death by 2030. In the U.S., where nearly 5 million people are diagnosed with emphysema, it already holds this position with one person dying every 4 minutes from COPD. Debilitating and costly, nearly $50 billion was spent addressing the direct and indirect costs associated with COPD in the U.S. in 2010.